Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 327-339

  Härtter, Sebastian ^a   Sennewald, Regina ^a   Schepers, Cornelia ^a   Baumann, Sybille ^b   Fritsch, Holger ^a   Friedman, Jeffrey ^c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b CRS Clinical Research Services Mannheim GmbH   (Germany)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Clopidogrel; Comedication; Dabigatran etexilate; Pharmacodynamics; Pharmacokinetics; Thrombin inhibitor

Indexed keywords

CLOPIDOGREL; DABIGATRAN ETEXILATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG WITHDRAWAL; HEMATOMA; HEMATURIA; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NORMAL HUMAN; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; ANALYSIS OF VARIANCE; ANTITHROMBINS; AREA UNDER CURVE; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; BLEEDING TIME; BLOOD COAGULATION; CROSS-OVER STUDIES; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; GERMANY; HUMANS; MALE; METABOLIC CLEARANCE RATE; PARTIAL THROMBOPLASTIN TIME; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; THROMBIN TIME; TICLOPIDINE; YOUNG ADULT;

EID: 84877114222     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1304-8     Document Type: Article

References (30)

1. Buresly K, Eisenberg MJ, Zhang X, Pilote L (2005) Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165:784-789
2. Johnson SG, Witt DM, Eddy TR, Delate T (2007) Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service. Chest 131:1500-1507
3. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45:1757-1766
4. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98:155-162
5. Weitz JI (2007) Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 5(Suppl 1):65-67
6. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386-399
7. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292-303
8. European Medicines Agency (2011) Pradaxa: summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000829/WC500041059.pdf. Accessed September 12, 2011
9. Taubert D, Von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schomig A, Schomig E (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486-501
10. Sikka P, Bindra VK (2010) Newer antithrombotic drugs. Indian J Crit Care Med 14:188-195
11. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, Maffrand JP (1992) Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 44:527-532
12. Steinhubl SR (2010) Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation 121:481-483
13. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92-99
14. L'Allier PL, Ducrocq G, Pranno N, Noble S, Ibrahim R, Gregoire JC, Azzari F, Nozza A, Berry C, Doucet S, Labarthe B, Theroux P, Tardif JC (2008) Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J Am Coll Cardiol 51:1066-1072
15. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di SG (2005) Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111:2099-2106
16. Von Beckerath N, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112:2946-2950
17. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C (2004) High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25:1903-1910
18. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF (2004) Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 35:2362-2367
19. Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, Lacreta F, Cheng S, Sultan E (2011) Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men. J Clin Pharmacol. doi: 10.1177/0091270011419852
20. Elashoff J (2005) NQuery advisor version 6.0 user's guide. Statistical Solutions, Cork
21. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, Von Beckerath N, Kastrati A (2010) Cytochrome 2 C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121:512-518
22. Sutor AH, Bowie EJ, Owen CA Jr (1971) Effect of aspirin, sodium salicylate, and acetaminophen on bleeding. Mayo Clin Proc 46:178-181
23. Weston MJ, Rubin MH, Langley PG, Westaby S, Williams R (1977) Effects of sulphinpyrazone and dipyridamole on capillary bleeding time in man. Thromb Res 10:833-840
24. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363-2372
25. Wahlander K, Eriksson-Lepkowska M, Nystrom P, Eriksson UG, Sarich TC, Badimon JJ, Kalies I, Elg M, Bylock A (2006) Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thromb Haemost 95:447-453
26. Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2007) Co-administration of rivaroxaban - a novel, oral, direct factor Xa inhibitor - and clopidogrel in healthy subjects [abstract]. Eur Heart J 28(CD)(Suppl):189. Abstr P1272
27. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81
28. Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59-98
29. Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15(Suppl 1):9S-16S
30. Härtter S, Sennewald R, Rathgen K, Nehmiz G, Reilly P (2011) Increase in the oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil. Presented at the 112th Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Dallas, TX, USA, 2-5 March 2011